SCHEMBL1704816

SCHEMBL1704816

C[C@@H]1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MLNR O43193 15/20 0.74
CYP3A4 P08684 5/20 0.74
ALDH1A1 P00352 2/20 0.46
CYP2D6 P10635 1/20 0.46
GHSR Q92847 1/20 0.46
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PRKAB2 O43741 1/20 0.41
PRKAG1 P54619 1/20 0.41
PRKAA2 P54646 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKAG3 Q9UGI9 1/20 0.41
PRKAG2 Q9UGJ0 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
DNMT3A Q9Y6K1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175700 0.90 MLNR (0.79) MLNRCYP3A4CYP2D6GHSRPRKAB2
SCHEMBL4597013 0.90 MLNR (0.79) MLNRCYP3A4CYP2D6GHSRPRKAB2
SCHEMBL1704684 0.88 MLNR (0.71) MLNRCYP3A4ALDH1A1CYP2D6GHSR
SCHEMBL1703823 0.87 MLNR (0.70) MLNRCYP3A4ALDH1A1CYP2D6GHSR
SCHEMBL4597349 0.87 MLNR (0.70) MLNRCYP3A4ALDH1A1CYP2D6GHSR
SCHEMBL1704589 0.85 MLNR (1.00) MLNRCYP3A4CYP2D6GHSR
SCHEMBL5125893 0.81 MLNR (0.74) MLNRCYP3A4CYP2D6GHSR
SCHEMBL1704580 0.77 MLNR (0.41) MLNRCYP3A4ALDH1A1MAPTRAB9A
SCHEMBL1312677 0.77 MLNR (0.57) MLNRCYP3A4CYP2D6GHSR
SCHEMBL4595783 0.76 HRH3 (0.44) MLNRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP disclosed